ERBB2 is overexpressed in 20–30% of breast cancers, and the monoclonal antibody Trastuzumab (Herceptin) that targets ERBB2 has been used with success to treat these (Slamon et al, 2001). This evidence concerns the gene ERBB2 and breast carcinoma.